BTIG analyst Timothy Chiang reiterated a Buy rating and $190 price target on Sarepta Therapeutics (NASDAQ: SRPT), noting 2019 is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE